GAMING

HANNOVER, Germany -- BioVisioN AG, Hannover, and the international pharmaceutical company AstraZeneca have signed a collaboration agreement. The collaboration will focus on the discovery of new biomarkers of inflammatory disease. BioVisioN will apply its unique phenotyping approach, which is based on the high resolution profiling of peptides and small proteins. It combines BioVisioN's proprietary Peptidomics(TM) technology with other quality-controlled processes and bioinformatics into a powerful analysis tool for the correlation with clinical condition and/or therapeutic outcomes. "This collaboration combines in an ideal way AstraZeneca's expertise on the pathophysiology of inflammatory diseases and access to clinically well defined diagnostic samples with the expertise of BioVisioN on the discovery and the validation of peptidic biomarkers. We look forward to applying our experience and the tools we have developed to search for novel biomarkers of inflammatory disease", says Dr. Sven Rohmann, CEO of BioVisioN.